Russia-developed personalized mRNA cancer vaccine begins clinical application

The Russian Ministry of Health announced on the 1st that Russia’s personalized mRNA (messenger RNA) cancer vaccine has begun clinical use, with a doctor administering this customized mRNA vaccine to a melanoma patient.
According to a post on the Russian Ministry of Health’s social media, the 60-year-old resident of Kursk Oblast who received the vaccine has melanoma.
Considering the patient’s condition, the doctor decided to administer the personalized mRNA cancer vaccine to prevent further deterioration.
The vaccination plan is phased, with the second and third doses given on the 8th and 15th days after the initial injection, respectively, with doses gradually increasing, followed by injections every 21 days, up to a maximum of 10 doses.
It is reported that this vaccine is currently suitable for adult melanoma patients who cannot have tumors surgically removed or have metastases, and the vaccine is customized based on the molecular genetic characteristics of the patient’s tumor, including specific tumor antigen information, enabling the immune system to recognize and destroy tumor cells.
The vaccine can also be used in combination with other immunotherapies.
Russian Health Minister Mikhail Murashko said that the mRNA personalized cancer vaccine will be included in Russia’s national health insurance plan to benefit more residents.
(Xinhua News Agency)